SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St futures tick higher after tech rout; Mideast, tariffs in focus
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Meta’s new seller app hits eBay where it hurts most
- Pullback in chip stocks is a buying opportunity, Citi says
Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update
November 3, 2016 6:30 AM EDTPositive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U.
Ongoing Phase 3 STATUS Trial Expected to be Sufficient to Support a European Marketing Authorization Application for SAGE-547 in SRSE
Eight Clinical Trials Across Pipeline Expected to Generate Top-Line Data in 2017
Moving into Next Strategic Phase - a Multi-Product, Neuropsych Development Portfolio
Conference Call Today at 8:00 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ:... More
